Dexcom (DXCM) director granted 7,166 RSUs at $0 on 10/24/2025
Dexcom, Inc. (DXCM) reported that director Euan Ashley acquired 7,166 restricted stock units on 10/24/2025 via a Form 4 filing.
Rhea-AI Filing Summary
Dexcom, Inc. (DXCM) reported that director Euan Ashley acquired 7,166 restricted stock units on 10/24/2025 via a Form 4 filing.
The RSU grant was recorded at a $0 price and is scheduled to vest in three equal annual installments from the grant date. Following this transaction, the reporting person beneficially owned 7,166 shares, held with direct ownership.
Positive
- None.
Negative
- None.
Insights
Routine director RSU grant; minimal immediate impact.
The filing records a standard equity compensation event: 7,166 RSUs granted to a Dexcom director on 10/24/2025 at $0. RSUs align director incentives with shareholder value and do not involve cash outlay.
Vesting in three equal annual installments spreads recognition over time, typical for director awards. Dilution impact from this single grant is likely immaterial, and no sale occurred. Key details include 7,166 shares beneficially owned after the grant, held directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 7,166 | $0.00 | $0.00 |
Footnotes (1)
- F1. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
FAQ
What did Dexcom (DXCM) disclose in this Form 4?
How many RSUs were granted to the Dexcom (DXCM) director and at what price?
What is the vesting schedule for the Dexcom (DXCM) RSUs?
What is the ownership form reported for these Dexcom (DXCM) securities?
What security type is involved in the Dexcom (DXCM) Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.